Hagedorn Research Institute

Department of Stem Cell Biology

Niels Steensens vej 6

DK-2820 Gentofte




Project leader

Dr. Mattias Hansson
Phone +45 4442 9137
Fax +45 4443 8000

Project staff

Dr. Christian le Fèvre Honoré
Fax +45 4443 8000


Dr. Nicolaj  Strøyer Christophersen   
Phone +45 4442 4047
Fax +45 4443 8000

Institute presentation

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Hagedorn Research Institute (HRI) in Gentofte, Denmark is a fully integrated part of Novo Nordisk. Our vision is to find a cure for diabetes and its complications and to identify new opportunities for treating diabetes. Our core focus is the effort to identify new biology-based targets for potential drugs to feed Novo Nordisk’s pipeline within the key areas of diabetes pathogenesis, treatment and cure. The aim of the Stem Cell Biology department is to develop cell replacement therapy into a viable option for treating Diabetes Mellitus. The reconstitution of a functional beta cell mass can restore blood glucose homeostasis in diabetic patients and eliminates the need for insulin injections. Our main objective is to generate clinical-grade pancreatic beta cells from pluripotent stem cells by harnessing their differentiation potential and to recapitulate the complex process of beta cell formation in vitro.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Until you give your consent, only those cookies necessary to maintain the website's functionality are active. When you choose "OK", so called third-party non-functional cookies (e.g. GDPR-conform Google Analytics) may also become active. Please be aware that the website's functionality may be restricted if you choose "DECLINE". You can revoke your choice at any time by clearing your browser cache/history and updating your selection. Please also view our privacy policy.
Ok Decline